Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

Johnson & Johnson Tops Q1 Earnings Forecast On Consumer Unit Gains, Boosts Dividend

“Our first quarter results demonstrate strong performance across all three segments of our business," said CEO Joaquin Duato.

The Street

Stocks Edge Higher, Netflix Earnings, Goldman On Deck, Johnson & Johnson, Nvidia Upgrade - Five Things To Know

Stock futures build gains, Treasury yields rise, with earnings in focus; Netflix nudges higher as investors eye paid sharing effect on profits; Goldman Sachs gains as bank earnings re-take center stage on Wall Street; Johnson & Johnson earnings on deck with Kenvue IPO, talc bankruptcy in focus and Nvidia shares…

The Street

Jim Cramer Bluntly Schools Stock-Buyers On 3 'Amazing American' Companies

The CNBC host offers some pointed thoughts.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

US pharma giant Johnson & Johnson seeks to settle baby powder case

US pharmaceutical giant Johnson & Johnson has offered to pay almost $9 billion to settle tens of thousands of lawsuits alleging that its talcum powder caused ovarian cancer. If approved by a court in the US state of New Jersey, the payout would be one of largest liability settlements in…

France 24

Dow Jones Rises, Nasdaq Falls As Investors Pour Into Gold; Health Care Stock Breaks Out

Johnson & Johnson raised its proposed combined settlement for thousands of talc cancer cases. Google's touts its AI chip model capabilities.

Investors Business Daily

Johnson & Johnson Pops After Sweetening Its Talc Settlement By Nearly $7 Billion

J&J reached an $8.9 billion settlement in ongoing litigation over its talc-based baby powders, leading JNJ stock to rise Wednesday.

Investors Business Daily

Dow Jones Reverses After ADP Jobs Data; C3.ai Continues To Plunge After Short-Seller Letter

The Dow Jones reversed higher Wednesday morning after ADP's jobs data. AI stock C3.ai plunged another 12% after Tuesday's short-seller letter.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Stocks Edge Lower, Johnson & Johnson Talc Settlement, Walmart Investor Day, FedEx Cost Cuts, C3.AI Slumps -Five Things To Know

Stock futures edge lower as stagflation concerns clip sentiment; Johnson & Johnson shares gain on new talc settlement plans; Walmart slips lower as retailer confirms 2023 profit outlook ahead of investor day; FedEx to detail cost-cutting plans at drive program update and C3.Ai shares extend slump as short-seller alleges 'serious'…

The Street

First Thing: Trump attacks hush money case in grievance-filled Mar-a-Lago speech

Former president appeared subdued in New York, only to return to his inflammatory ways in Florida. Plus, the campaigners using using dating apps to boost voter turnout

The Guardian - UK

Johnson & Johnson offers $9billion to settle talcum powder cancer claims

Johnson & Johnson is reportedly facing over 40,000 lawsuits from customers who claimed using the company's talc-based baby powder caused cancer

Daily Mirror

Here's 3 Dividend Companies That Just Crossed Above Their 50 Moving Average

Trading Smarter, Not Harder With the 50-Day Moving Average Strategy

Barchart

Johnson & Johnson proposes paying $8.9 billion to settle talcum powder lawsuits

Under a proposal, a J&J subsidiary will re-file for bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history.

WEKU

Johnson & Johnson proposes $8.9 billion payout to settle talcum powder lawsuits

A subsidiary of the company will re-file for Chapter 11 bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history.

Chicago Sun-Times

Dow Jones Futures: AI Stock Keeps Sliding; Johnson & Johnson Rises

Futures: The indexes held up OK Tuesday amid recession fears, but breadth was weak. AI stock C3.ai kept falling overnight. J&J stock rose..

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Buy Johnson & Johnson Stock and Its 3% Dividend Yield?

Johnson & Johnson stock in Q1 declined for nine straight weeks. Is that the selloff that long investors had been waiting for?

WEKU

As states start to get opioid settlement cash, few are sharing how they spend it

All told, drugmakers and distributors will pay over $50 billion to communities harmed by opioids. An investigation finds that only a dozen states are letting the public see how they use the money.

Investors Business Daily

J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out

Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out.

The Guardian - UK

Victory over big pharma opens door to cheaper tuberculosis drugs

India’s patent office turns down bedaquiline extension to Johnson & Johnson, clearing the way for generic versions

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

The Strongest Pharma Stock This Week

Tighter bank lending and the Fed’s continued fight against inflation will likely push the economy into a recession this year. In this scenario, investors can look to invest in the pharma giant Johnson & Johnson (JNJ), given its financial strength, reliable dividend payments, and solid growth prospects. Read more….

StockNews.com

Want to Retire a Millionaire? 2 Stocks to Buy Now

The recent bank failures have increased the likelihood of a recession, with many economists increasing the odds of an economic slump in the next 12 months. Amid this backdrop, investors could buy fundamentally strong stocks, Johnson & Johnson (JNJ) and Pfizer (PFE), which could help retire a millionaire. Read on.

StockNews.com

This Big Pharma Stock Is a Clear Buy in 2023

With interest rates expected to be higher than originally anticipated and fears of a looming recession weighing heavily on investors’ decisions, the stock market is expected to remain under pressure this year. Amid this backdrop, it could be wise for investors to invest in Johnson & Johnson (JNJ) due to…

StockNews.com

3 Powerhouse Stocks to Buy in 2023

As the Fed is expected to raise interest rates higher than expected, the revived recession fears will keep the stock market under pressure in the upcoming months. Thus, it could be wise to scoop up shares of high-quality businesses, such as Johnson & Johnson (JNJ), Humana Inc. (HUM), and AutoZone,…

StockNews.com

1 Stock to Buy for Safety in This Volatile Market

With the Fed anticipating higher interest rate hikes than previously expected, the stock market is expected to remain volatile in the upcoming months. Given its strong balance sheet, brand recognition, and solid dividend payouts, it could be safe to invest in Johnson & Johnson (JNJ). Read more….

Investors Business Daily

How To Use Covered Calls To Get 17% Annualized Return On JNJ Stock

Selling the May 155 call option generates an income of 3.42% in just over two months, equaling around 17% annualized.

The Street

Buy the Dip in Johnson & Johnson and Its Near-3% Dividend Yield

Johnson & Johnson stock has fallen in seven straight weeks, trades at less than 15 times earnings and pays a near-3% dividend yield. Plus, support is nearby.

1 … 6 7 8 9

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations